PharmaEssentia’s BESREMi (ropeginterferon alfa-2b-njft) Now Available for the Treatment of People With Polycythemia Vera in the United States -…
Awards and Honors: Winter 2021 | Department of Medicine News | Stanford Medicine – Stanford Medicine
BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced that BESREMi (ropeginterferon alfa-2b-njft) is now commercially available in the U.S. to eligible patients with polycythemia vera (PV). BESREMi was approved by the FDA in November as the only interferon for adults with polycythemia vera
Here’s Why Longeveron Is Surging Today – Motley Fool
Department of Medicine Faculty and Staff Named 2021 ISP Award Winners Many projects have been recognized as part of Stanford Medicines Integrated Strategic Plan (ISP), and the ISP Awards highlight individualsand teamsfrom the Stanford Medicine community who, through their extraordinary efforts, embody the strategic priorities of our Integrated Strategic Plan (ISP): Value Focused, Digitally Driven, and Uniquely Stanford.
Global Regenerative Medicine Partnering Report/Directory 2021: Terms and Agreements for 1600 Deals 2014-2 – Benzinga
What happened Shares of Longeveron (NASDAQ:LGVN), a clinical-stage biotechnology company headquartered in Miami, are soaring in response to good news from the U.S.
CAR T-Cell Therapy Market is anticipated to reach US$ 2.8 Bn by 2031 – PRNewswire
The "Global Regenerative Medicine Partnering Terms and Agreements 2014 to 2021" report has been added to ResearchAndMarkets.com's offering. The Global Regenerative Medicine Partnering Terms and Agreements 2014-2021 report provides comprehensive understanding and unprecedented access to the regenerative medicine including cell therapy, organ regeneration, stem cells and tissue regeneration partnering deals and agreements entered into by the worlds leading healthcare companies.
Stem-cell implant prototypes pave the way towards life-long treatment for type 1 diabetes – ZME Science
For instance, in December 2017, Gilead Science acquired Cell Design Labs Inc., which is a privately held company of biotherapeutics that discovers and develops cell-based therapies. This acquisition benefits Gilead through gaining novel technology platforms that will its boost R&D efforts in cellular therapy.
Certain Patients With Heart Failure May Benefit From Stem Cell Therapy – Pharmacy Times
New research is paving the way towards reliable, long-term treatments for type 1 diabetes. The work focused on developing implants based on stem cells that can deliver insulin directly into the bloodstream of diabetes patients.
Humanigen Announces Conference Call and Webcast to Discuss Lancet Respiratory Medicine Publications and Provide a Corporate Update – Yahoo Finance
Stem cell therapy was associated with a reduction of the number of heart attacks, strokes, and death among people with chronic, high-risk, NYHA class 2 or 3 heart failure with reduced ejection fraction (HFrEF), according to a study presented at the American Heart Associations Scientific Sessions 2021. The investigators found this improvement was especially pronounced among patients who had higher levels of inflammation. The rate of hospitalization was not reduced.
Roundtable Discussion: Usmani and Participants Review Using Transplant and Combination Therapy in a Patient With Newly Diagnosed Multiple Myeloma -…
BURLINGAME, Calif., December 01, 2021--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm, announced that it will host a conference call and webcast to discuss The Lancet Respiratory Medicine publications and provide a corporate update at 8am EST on December 2, 2021
Hematopoiesis and innate immunity: an inseparable couple for good and bad times, bound together by an hormetic relationship – DocWire News
A 51-year-old man presented with worsening fatigue on exertion and pallor with an ECOG performance score of 2 and was diagnoses with stage II standard-risk multiple myeloma. During a Targeted Oncology Case-Based Roundtable event, Saad Zafar Usmani, MD, MBA, chief, Plasma Cell Disorders Program, director, Clinical Research in Hematologic Malignancies, Levine Cancer Institute, Atrium Health, discussed the case of a 51-year-old patients with newly-diagnosed multiple myeloma with 6 peers. USMANI: How do you discuss the prognosis with your patients
This article was originally published here Leukemia.